Get started
Author

Daniel Stellato

Observed names: D. Stellato, Daniel R Stellato, Daniel R. Stellato, Stellato, Daniel
OpenAlex ID: A5086133015
Preferences of Canadian Patients and Physicians for Adjuvant Treatments for Melanoma
2019 · D. Stellato, M. Thabane, et al. · Current Oncology · 17
PDF
Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective
2019 · Margaret E. Gerbasi, Daniel Stellato, et al. · Journal of Medical Economics · 14
Preferences of Canadian Patients and Physicians for Treatment of HR+/HER2− Advanced Breast Cancer
2021 · Daniel Stellato, Marroon Thabane, et al. · Current Oncology · 11
PDF
Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2− Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrine Therapy: A Canadian Healthcare Perspective
2021 · Daniel Stellato, Marroon E. Thabane, et al. · PharmacoEconomics · 7
Cost Effectiveness of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Pre-/Perimenopausal, HR+ and HER2− Advanced Breast Cancer: A Canadian Healthcare Perspective
2021 · Daniel Stellato, Marroon E. Thabane, et al. · PharmacoEconomics · 7
Budget Impact of Dabrafenib and Trametinib in Combination as Adjuvant Treatment of BRAF V600E/K Mutation-Positive Melanoma from a U.S. Commercial Payer Perspective
2019 · Daniel Stellato, Margaret E. Gerbasi, et al. · Journal of Managed Care & Specialty Pharmacy · 6
PDF
Pcn87 Cost-effectivness Analysis of Dabrafenib Plus Trametinib as Adjuvant Treatment for Braf V600 Mutation-positive Melanoma After Surgical Resection in Canada- a Societal Perspective
2019 · D. Stellato, M. Thabane, et al. · Value in Health · 3
PDF
Matching-adjusted indirect comparison of ribociclib + nonsteroidal aromatase inhibitor versus abemaciclib + endocrine therapy in hormone receptor-positive/HER2-negative early breast cancer
2025 · Stephen Chia, Jie Li, et al. · Journal of Comparative Effectiveness Research · 1
PDF
212P Cost-effectiveness analysis of ribociclib plus endocrine therapy (ET) versus ET alone in the adjuvant treatment of stage II and III pre and postmenopausal women with HR+/HER2− early breast cancer (EBC): A Canadian payer perspective
2025 · C. Brezden-Masley, D. Soliman, et al. · ESMO Open · 1
PDF
Pcn128 Cost-effectiveness of Ribocilib Plus Fulvestrant (r+f) Vs Fulvestrant (ful) in Hormone Receptor–positive, Human Epidermal Growth Factor Receptor 2–negative (hr+/her2-) Advanced Breast Cancer (abc): a Canadian Healthcare Perspective
2020 · D. Stellato, M. Thabane, et al. · Value in Health · 1
Pcn87 Cost-effectiveness of Ribocilib Plus Nonsteroidal Aromatase Inhibitor (nsai) in Hormone Receptor–positive, Human Epidermal Growth Factor Receptor 2–negative (hr+/her2-) Advanced Breast Cancer (abc): a Canadian Healthcare Perspective
2020 · D. Stellato, M. Thabane, et al. · Value in Health · 1
Cost-Effectiveness Analysis of Ribociclib plus an Aromatase Inhibitor (AI) Versus AI Alone in the Adjuvant Treatment of Stage II and III Pre- and Postmenopausal Women with HR+/HER2− Early Breast Cancer (EBC): A Canadian Payer Perspective
2026 · Dina Soliman, Christine Brezden-Masley, et al. · PharmacoEconomics - Open
PDF
Ee43 Cost-effectiveness Analysis of Ribociclib Plus Endocrine Therapy (et) Versus Abemaciclib Plus Et in the Adjuvant Treatment of Node Positive Pre and Postmenopausal Women With Hr+/her2- Early Breast Cancer (ebc): a Canadian Payer Perspective
2026 · Dina Soliman, Sandeep Sehdev, et al. · Value in Health
PDF
Comparative cost-effectiveness of ribociclib and palbociclib as first-line treatment for HR+/HER2– advanced breast cancer in postmenopausal women: analysis from a Medicare perspective
2025 · Sarah Sammons, Paolo Tarantino, et al. · Journal of Medical Economics
PDF
Cost-effectiveness analysis of ribociclib versus abemaciclib as first-line treatments for postmenopausal women with HR+/HER2– advanced breast cancer: a Medicare perspective
2025 · Paolo Tarantino, Sarah Sammons, et al. · Journal of Medical Economics
PDF
Survival Outcomes in Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Receiving Third- or Subsequent Line (3L) Treatment
2017 · Daniel R. Stellato, Lisa McGarry, et al. · Clinical Lymphoma Myeloma & Leukemia
Survival outcomes in patients with chronic phase chronic myeloid leukemia (CP-CML) receiving third- or subsequent line (3L) treatment prior to the availability of ponatinib.
2017 · Daniel R Stellato, Lisa McGarry, et al. · Journal of Clinical Oncology
Works count: 18
Citation count: 69
H-index: 6
I10-index: 3
Year
Topic
Type